source
- BioNTech, DualityBio weigh future of HER2 ADC after modest Phase 3 breast cancer resultsBioNTech and DualityBio are assessing next steps for their HER2-targeted antibody-drug conjugate trastuzumab pamirtecan after a Phase 3 trial in breast cancer. The trial met its primary endpoint,…
- Patient feels exhausted despite normal labs, highlighting stress and lifestyle factorsA family nurse practitioner recounts a visit with a 43-year-old patient who complains that she no longer has the energy she had in her twenties. The doctor notes that all of the patient’s lab resu…